- Home
- NNVC vs VYNE Comparison
NNVC vs VYNE Comparison
Compare NNVC & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NNVC | VYNE |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.8M | 19.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | NNVC | VYNE |
|---|---|---|
| Price | $1.03 | $0.59 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 289.0K | ★ 418.2K |
| Earning Date | 02-13-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $524,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.29 |
| 52 Week Low | $0.85 | $0.28 |
| 52 Week High | $2.23 | $2.94 |
Technical Indicators
Market Signals| Indicator | NNVC | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 68.94 |
| Support Level | $0.93 | $0.55 |
| Resistance Level | $1.05 | $0.57 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 65.22 | 91.01 |
Price Performance
Historical ComparisonAbout NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.